Arusha Arabica (Coffea arabica 'Arusha')

Arusha Arabica (Coffea arabica 'Arusha') is a tall Ethiopian-origin coffee cultivar grown primarily in Tanzania and Papua New Guinea, containing caffeine, chlorogenic acids, and diterpenes such as cafestol and kahweol as its principal bioactive compounds. Its physiological effects are attributable to caffeine's antagonism of adenosine A1 and A2A receptors and chlorogenic acid's inhibition of glucose-6-phosphatase, though no cultivar-specific clinical research exists to distinguish it from standard Coffea arabica.

Origin & History

Arusha Arabica (Coffea arabica 'Arusha') is a rare coffee cultivar variant grown in the highlands of Tanzania (including Arusha, Moshi, Kigoma, and Tarime) and Papua New Guinea at altitudes over 5,000 feet. The Specialty Coffee Association classifies it as related to Bourbon coffee due to its rounder fruits and wider leaves, with beans harvested from red cherries through standard wet or dry milling processes.

Historical & Cultural Context

Arusha Arabica has no documented historical use in traditional medicine systems. It is primarily a modern specialty coffee cultivar grown for beverage production in Tanzania, with no evidence of medicinal application in African, Ayurvedic, or other traditional healing systems.

Health Benefits

• No clinical health benefits documented - no human trials exist for this specific cultivar
• General C. arabica effects may apply but are not cultivar-specific (evidence quality: absent)
• No differentiation from standard coffee benefits in available research
• No biomedical studies distinguish Arusha from other arabica varieties
• Cultivar grown primarily for specialty beverage production, not medicinal use

How It Works

Caffeine present in Arusha Arabica competitively antagonizes adenosine A1 and A2A receptors in the central nervous system, increasing dopaminergic and noradrenergic neurotransmission and reducing perceived fatigue. Chlorogenic acids, particularly 5-caffeoylquinic acid, inhibit hepatic glucose-6-phosphatase and slow intestinal glucose absorption by modulating sodium-glucose cotransporter 1 (SGLT1) activity. Diterpenes cafestol and kahweol act as ligands for the farnesoid X receptor (FXR) and pregnane X receptor (PXR), influencing bile acid metabolism and upregulating antioxidant enzymes such as glutathione S-transferase, though these mechanisms have not been validated specifically for the Arusha cultivar.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specific to Arusha Arabica were identified in the research. While general C. arabica studies exist for coffee-related effects, none differentiate this cultivar, and no PubMed PMIDs are available for Arusha-specific research.

Clinical Summary

No published human clinical trials, animal studies, or in vitro investigations have examined the Arusha cultivar specifically or compared its bioactive profile against other Coffea arabica varieties. Extrapolated evidence from broad Coffea arabica research includes randomized controlled trials in hundreds to thousands of participants demonstrating associations between habitual coffee consumption (3–5 cups/day, approximately 300–500 mg caffeine) and reduced risk of type 2 diabetes, Parkinson's disease, and all-cause mortality, but these findings cannot be attributed to Arusha genetics. Chlorogenic acid content varies meaningfully across arabica cultivars depending on altitude, soil, and processing, meaning phytochemical potency of Arusha beans is uncharacterized relative to clinical study samples. The overall evidence quality for any Arusha-specific health claim is absent, and consumers should rely only on general arabica coffee data until cultivar-specific research is conducted.

Nutritional Profile

Arusha Arabica (Coffea arabica 'Arusha') shares the general nutritional composition of C. arabica green and roasted beans, with cultivar-specific data absent from published literature. As roasted coffee beverage (per 240ml/8oz brewed cup): Calories 2-5 kcal, Carbohydrates 0g, Protein 0.3g, Fat 0g, Fiber 0g. Key bioactive compounds: Caffeine approximately 80-120mg per 8oz cup (C. arabica typically ranges 1.2-1.5% caffeine by dry weight in green beans, lower than C. canephora); Chlorogenic acids (CGAs) 70-200mg per cup, predominantly 5-caffeoylquinic acid (5-CQA), representing the primary antioxidant fraction; Trigonelline 60-120mg per cup, partially degraded to niacin (vitamin B3, yielding approximately 1-3mg niacin equivalent) during roasting. Kahweol and cafestol (diterpene lipids) present at low concentrations in filtered brew (~0.2-0.5mg/cup filtered; significantly higher in unfiltered/French press preparations 3-6mg/cup). Potassium approximately 116mg per cup. Magnesium approximately 7mg per cup. Niacin (B3) 0.5mg per cup. Riboflavin (B2) trace amounts (~0.01mg). Melanoidins (Maillard reaction polymers) 200-500mg per cup, contributing antioxidant and prebiotic activity. Total antioxidant capacity approximately 200-550mg Trolox equivalents per cup. Arusha is a tall Ethiopian-lineage cultivar grown on Mt. Meru/Tanzania at high altitude; high-altitude growth generally correlates with slower cherry maturation and potentially higher sugar and CGA concentrations relative to lower-altitude arabicas, though no published quantified data confirms cultivar-specific deviation from general arabica ranges. Bioavailability: CGAs are absorbed 33% in small intestine, remainder metabolized by colonic microbiota to dihydrocaffeic and dihydroferulic acids; caffeine bioavailability is near 100% via oral route.

Preparation & Dosage

No clinically studied dosage ranges exist for Arusha Arabica in any form (extract, powder, or standardized preparations), as no biomedical trials have been conducted on this cultivar. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - no biomedical research exists

Safety & Interactions

As a Coffea arabica cultivar, Arusha coffee carries the established safety profile of caffeinated coffee: doses exceeding 400 mg caffeine per day in healthy adults are associated with anxiety, insomnia, tachycardia, and elevated blood pressure. Caffeine is a substrate and inhibitor of CYP1A2, creating clinically relevant interactions with fluvoxamine, ciprofloxacin, clozapine, and theophylline, which can raise plasma caffeine levels and increase adverse effect risk. Chlorogenic acids may modestly enhance the hypoglycemic effect of antidiabetic medications including metformin, warranting blood glucose monitoring in diabetic individuals. Caffeine consumption during pregnancy should be limited to under 200 mg per day per WHO and ACOG guidelines due to associations with fetal growth restriction, and cafestol and kahweol from unfiltered preparations may raise LDL cholesterol in individuals with lipid disorders.